Analysis of the efficiency and safety of using the slow-release calcium channel blocker nifedipine as a tocolytic drug in pregnant women with preterm labor

DOI: https://doi.org/10.29296/25877305-2021-01-02
Download full text PDF
Issue: 
1
Year: 
2021

K. Akopov(1), E. Zhukova(2), Candidate of Medical Sciences; E. Sokova(3), Candidate of Medical
Sciences; Professor R. Chilova(2), MD (1)S.S. Yudin City Clinical Hospital, Moscow Healthcare Department
(2)I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
(3)Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow

Preterm labor (PL) remains one of the major problems of modern obstetrics all over the world, which is due to the unresolved issues concerning etiology, pathogenesis, clinical presentation, diagnosis, and rational pharmacotherapy. PL complications are the main cause of neonatal death worldwide; with the surviving infants facing the risk of serious neonatal complications and long-term disability. In the course of prioritization work, the WHO has placed PL in the top 10 research priorities for the period up to 2025. The investigations aimed at preventing PL and reducing perinatal mortality are also a key component of the UN global strategy for sustainable development until 2030. The development and introduction of technologies for personalized medicine are ways to optimize tocolytic therapy in pregnant women with PL, which are regulated in the Russian Strategy for the Development of Medical Science until 2025.
Keywords: 
obstetrics and gynecology
preterm labor
tocolysis
nifedipine

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Instruktsija po primeneniju lekarstvennogo preparata dlja meditsinskogo primenenija Nifedipin. Gosudarstvennyj reestr lekarstvennyh sredstv [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Nifedipin. Gosudarstvennyi reestr lekarstvennykh sredstv (in Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t=
  2. Klinicheskie rekomendatsii «Prezhdevremennye rody» (utv. Minzdravom Rossii) [Klinicheskie rekomendatsii «Prezhdevremennye rody» (utv. Minzdravom Rossii) (in Russ.)]. URL: http://cr.rosminzdrav.ru/
  3. Lepahin V.K. i dr. Neblagoprijatnye pobochnye reaktsii, vyzyvaemye tokoliticheskimi preparatami. Bezopasnost' lekarstv i farmakonadzor. 2009; 2: 29–38 [Lepakhin V.K. i dr. Neblagopriyatnye pobochnye reaktsii, vyzyvaemye tokoliticheskimi preparatami. Bezopasnost’ lekarstv i farmakonadzor. 2009; 2: 29–38 (in Russ.)].
  4. Nazarova A.O., Malyshkina A.I., Nazarov S.B. Faktory riska spontannyh prezhdevremennyh rodov: rezul'taty kliniko-epidemiologicheskogo issledovanija. Akusherstvo i ginekologija. 2019; 9: 82–6 [Nazarova A.O., Malyshkina A.I., Nazarov S.B. Risk factors for spontaneous preterm birth: results of a clinical-epidemiological study. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2019; 9: 82–6 (in Russ.)]. https://dx.doi.org/10.18565/aig.2019.9.82-86
  5. Personalizirovannaja meditsina: kliniko-farmakologicheskie aspekty. Pod red. V.G. Kukesa M.: Izdatel'stvo AGO Mezhdunarodnaja assotsiatsija klinicheskih farmakologov i farmatsevtov, 2014; 260 s. [Personalizirovannaya meditsina: kliniko-farmakologicheskie aspekty. Pod red. V.G. Kukesa M.: Izdatel’stvo AGO Mezhdunarodnaya assotsiatsiya klinicheskikh farmakologov i farmatsevtov, 2014; 260 s. (in Russ.)].
  6. Serov V.N., Suhorukova O.I. Profilaktika prezhdevremennyh rodov. RMZh. 2014; 1: 3–10 [Serov V.N., Sukhorukova O.I. Profilaktika prezhdevremennykh rodov. RMZh. 2014; 1: 3–10 (in Russ.)].
  7. Armstrong J., Goldfarb A., Instrum R. et al. Improvement evident but still necessary in clinical practice guideline quality: a systematic review. J Clin Epidemiol. 2017; 81: 13–21. DOI: 10.1016/j.jclinepi.2016.08.005
  8. Saleh S.S., Al-Ramahi M.Q., Al Kazaleh F.A. Atosiban and nifedipine in the suppression of pre- term labour: a comparative study. J Obstet Gynaecol. 2013; 33: 43–5. DOI: 10.3109/01443615.2012.721822
  9. Ashraf B. Efficacy and safety of oral nifedipine with or without vaginal progesterone in the management of threatened preterm labor. J Reprod Biomed (Yazd). 2019; 17 (9): 629–36. DOI: 10.18502/ijrm.v17i9.5098
  10. Berger I., Abele H., Bahlmann F. et al. Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) – Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes. Geburtshilfe Frauenheilkd. 2019; 79 (8): 813–33. DOI: 10.1055/a-0903-2735
  11. Clinical practice guideline tocolytic treatment in pregnancy. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland And Directorate of Strategy and Clinical Care Health Service Executive. Version 1.0 Date of publication: April 2013 Guideline No.22 Revision date: April 2015.
  12. Sachar M., Kelly E.J., Unadkat J.D. Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells. AAPS J. 2019; 21 (3): 45. DOI: 10.1208/s12248-019-0316-z
  13. Seredina T.A., Goreva O.B., Talaban V.O. et al. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet. 2012; 13 (1): 45. DOI: 10.1186/1471-2350-13-45
  14. Talati A.N., Hackney D.N., Mesiano S. Pathophysiology of preterm labor with intact membranes. Semin Perinatol. 2017; 41 (7): 420–6. DOI: 10.1053/j.semperi.2017.07.013
  15. Vogel J.P., Oladapo O.T., Manu A. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health. 2015; 3: e589–e590. DOI: 10.1016/S2214-109X(15)00183-7
  16. Yamasato K., Burlingame J., Kaneshiro B. Hemodynamic effects of nifedipine tocolysis. J Obstet Gynaecol Res. 2015; 41: 17–22. DOI: 10.1111/jog.12478